Skip to main content

Von Willebrand Disease

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
NCT00168090 | PHASE 4 | INTERVENTIONAL

The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.

Trial Information
30 Participants
Recruiting
18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov